THERAPY DOSSIER · th-db2b908e1e5d

Pleiotrophin (PTN)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25250571 ↗2014Reported benefit

Pleiotrophin mediates hematopoietic regeneration via activation of RAS.

MouseRadiationSystemic administration, route not specified in the abstractAfter irradiation and after myeloablative bone marrow transplantation

Model: Ionizing radiation exposure causing haematopoietic toxicity, and myeloablative bone marrow transplantation

Systemic pleiotrophin substantially increased survival after radiation exposure and after myeloablative bone marrow transplantation, accelerating recovery of bone marrow haematopoietic stem and progenitor cells. Pleiotrophin induced haematopoietic stem cell quiescence and activated RAS in PTPRZ-exp…

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…